Ceeto Capital Group’s Quest Diagnostics DGX Stock Holding History

Ceeto Capital Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,000	Closed	-$547K	–	156
2022 Q1	$547K	Hold	4,000	–	–	0.25%	96
2021 Q4	$692K	Hold	4,000	–	–	0.29%	77
2021 Q3	$581K	Sell	4,000 -7,072	-64%	-$1.03M	0.27%	84
2021 Q2	$1.46M	Hold	11,072	–	–	0.66%	44
2021 Q1	$1.42M	Hold	11,072	–	–	0.69%	42
2020 Q4	$1.32M	Hold	11,072	–	–	0.67%	43
2020 Q3	$1.27M	Hold	11,072	–	–	0.71%	40
2020 Q2	$1.26M	Hold	11,072	–	–	0.82%	36
2020 Q1	$889K	Buy	11,072 +1,072	+11%	+$111K	0.71%	43
2019 Q4	$1.07M	Hold	10,000	–	–	0.7%	43
2019 Q3	$1.07M	Hold	10,000	–	–	0.77%	36
2019 Q2	$1.02M	Hold	10,000	–	–	0.75%	42
2019 Q1	$899K	Hold	10,000	–	–	0.66%	49
2018 Q4	$833K	Hold	10,000	–	–	0.69%	49
2018 Q3	$1.08M	Hold	10,000	–	–	0.74%	45
2018 Q2	$1.1M	Hold	10,000	–	–	0.82%	39
2018 Q1	$1M	Hold	10,000	–	–	0.76%	44
2017 Q4	$985K	Hold	10,000	–	–	0.7%	45
2017 Q3	$936K	Buy	+10,000	New	+$1.06M	0.7%	45

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Ceeto Capital Group's DGX Position: Q2 2022 in Review

Ceeto Capital Group sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 4,000 shares — an estimated $547K sold.

Ceeto Capital Group first reported a position in DGX in Q3 2017 and held it in 19 quarters. The position peaked at $1.46M in Q2 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

Ceeto Capital Group reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
Ceeto Capital Group sold 4,000 Quest Diagnostics shares in Q2 2022, an estimated $547K.
Ceeto Capital Group first reported a position in Quest Diagnostics in Q3 2017 and held it in 19 quarters.
Ceeto Capital Group's Quest Diagnostics position peaked at $1.46M in Q2 2021.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Ceeto Capital Group's 13F filing for Q2 2022, filed 15 Aug 2022.